CXCL13-expressing CD4(+) T cells enhance anti-tumor immunity in NSCLC through lymphocyte triad formation
CXCL13-expressing CD4(+) T cells recruit CXCR5(+) B cells, forming a triad with CD8(+) T cells that enhances anti-tumor immunity.
Indication
Clinical and regulatory intelligence for NSCLC with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.